Eli Lilly CDR (CAD Hedged)

Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease work.

Trogenix completed a $95 million Series A financing led by IQ Capital to advance its Odysseus® platform for potentially curative cancer therapies.

Sitryx Therapeutics received FDA clearance for its IND application for SYX-5219, a first-in-class oral PKM2 modulator targeting atopic dermatitis.

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.

AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.

Nigeria has signed a memorandum of understanding with China's Shanghai Haiqi Industrial Company Limited to establish what Chinese officials describe as Africa's first local insulin production facility.

Prellis Biologics announced a multi-target drug discovery collaboration with Eli Lilly combining Prellis' EXIS™ organoid platform with Lilly's development expertise.

Pfizer is acquiring Metsera, a nine-month-old biotech company, for $7.3 billion to gain access to innovative obesity therapeutics including a once-monthly GLP-1 agonist.

Myricx Bio has appointed Mohit Rawat as CEO, bringing extensive biopharma experience from Fusion Pharmaceuticals, which was acquired by AstraZeneca for $2.4 billion in 2024.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Novo Nordisk's once-weekly injectable diabetes treatment Kyinsu for adults with type 2 diabetes.